ralph.dahinden

Kathi Mujynya

The “Schlieremer”: Women in the top leadership of companies

Article about our Chief Operations Officer, Mrs. Kathi Mujynya Ludunge, in the “Schlieremer” of November 2020

“It wasn’t always easy”

CUTISS’ management team consists of five people, including three women. One of them is 52-year-old Kathi Mujynya Ludunge. She has been Chief Operating Officer for a year. Until recently, CUTISS only had its research lab in Schlieren. The offices of the startup, which was founded in 2017, and the production facilities are now also located here. Mujynya Ludunge’s biggest challenge at the moment is therefore to establish and consolidate the operational structures in Schlieren, as well as to keep to the timelines and budget.

CUTISS is a life science company developing personalized skin grafting technologies for the treatment of a wide range of skin defects. European market approval for its most advanced product candidate, denovoSkin, is expected in 2023. Cutiss achieved 1st place in the “Top 100 Swiss Startup Award” competition this year. The company has thirty employees.

Mujynya Ludunge studied biology at the Ecole Supérieure de la Santé in Neuchâtel and subsequently completed a master’s degree in business administration at the University of Geneva. Later, she added a postgraduate diploma in Management of Biotech and Pharmaceuticals Venture at the EPF Lausanne. “I always wanted to have an overview and understand the big picture,” Mujynya Ludunge says of her current job. “At the same time, I want to positively develop organizations and share my energy and passion for science with others.” Mujynya Ludunge has led teams in Switzerland, the U.S. and Singapore over the past 18 years.

Her rise to leadership positions has “not always been easy,” Mujynya Ludunge explains. On the one hand, it was not common in the past for women to be represented at middle and senior management levels and also to be responsible for entire teams. On the other hand, she says, she is not only a woman, but also a “person of color” – her father is Congolese, her mother Swiss. “Fortunately, the world has become much more diverse in 2020,” Mujynya Ludunge says.

Mujynya Ludunge works between fifty and sixty hours a week. However, she is now getting better at not thinking about work on weekends, she says. She also has the good fortune of a large family, which keeps her busy in her private life. Mujynya Ludunge is married and the mother of five children. In her sparse free time, she reads a lot – “mainly between 11 p.m. and 1 a.m.”. She and her family also grow fruit and vegetables for their own use. With the garden’s harvest, she loves to cook for family and friends in the evenings and on weekends.

The “Schlieremer”: Women in the top leadership of companies Read More »

Article in SI Style: “You need to think big”

Article about our Chief Executive Officer, Dr. Daniela Marino, in SI Style of November 19, 2020

She preferred reading anatomy books to playing outside, even at the age of eight. Today, Daniela Marino heads the successful biotech startup Cutiss. What is her motivation? What is her superpower? And when was a day successful for her? We asked her 12 questions.

She grew up in Sicily as the daughter of a post office manager and an English teacher and had only one dream: to become a scientist. She studied biotechnology and came to Switzerland 15 years ago to do her PhD at ETH Zurich.

Daniela Marino aspired to an academic career, wanted to become a professor. But a research project changed everything. Today, the 39-year-old heads the life science company Cutiss, which produces personalized skin grafts. The innovative process involves growing new skin from the body’s own tissue. This reduces scarring in people with extensive skin injuries – and improves their quality of life. The University of Zurich spin-off has been showered with awards and funding for its groundbreaking idea. Around 30 employees recently moved into the brand-new headquarters, including a 500-square-meter laboratory, in Schlieren ZH.

Daniela Marino reveals how she went from scientist to founder, what she is particularly proud of and why she prefers to talk to herself in the interview format 12 Women, 12 Questions.

1) What’s the bravest thing you’ve ever done?

Becoming an entrepreneur. Business and management science had never interested me before, my world was science, my workplace was the lab. But when I saw the first test results of our invention, it was clear to me that we could really make a difference with it. Finding my role as CEO was a big challenge, not only professionally but also personally. But my motivation remains the same: I want to help people.

2) What are your principles as an entrepreneur?

The world deserves more entrepreneurs who are down-to-earth and honest. Sure, you need a vision, but to get to your goal you have to be very methodical. You always have to stay humble and take it one step at a time. It doesn’t do anyone any good to run headlong into a wall. Scientific thinking helps me to do just that. I’m very proud of my explorer brain. (laughs)

3) What people inspire you?

My idol from a very young age was the Italian Nobel Prize winner Rita Levi-Montalcini. In my childhood room, her poster hung next to Freddie Mercury’s. I think at one point my parents were quite worried because I wasn’t interested in boys like the other teen girls my age, preferring to read anatomy books and stories about knights and fairies all weekend long. My father believes that I inherited this fascination from his mother. She was never able to attend school, became a housewife. But in self-study she was engaged in astronomy and medicine.

4) How do you make difficult decisions?

I don’t wait too long, and I’m lucky in that I use my two brain hemispheres – the rational and the emotional – in a fairly balanced way. That is to say: First, I analyze the situation in detail, weighing the pros and cons of each piece of the puzzle. Then I let my instincts guide me. My head filters the options, my gut makes the decision.

5) When was a day successful for you?

When I’m not frustrated, my husband is not frustrated, our two children are not frustrated, and neither are my employees – in short, when everyone around me is happy. I realize that this can’t be the case every day, but it’s still my aspiration. And I believe that if the people around you see that you’re doing your best, they’ll be more forgiving of you if things don’t go smoothly.

6) What is your superpower?

My multitasking talent. The fact that I can be fully present to this conversation while thinking about what I need to get done this afternoon. That skill is almost essential for survival when you’re a mom and trying to build a company at the same time. Although I have to say that we don’t have a classic division of roles at our house: You rarely see me in the kitchen.

7) Where will your company be in five years?

We have grown very quickly and want to continue to be at the forefront of our field. In five years, we would like to be treating patients in Europe and be ready for the American market. Skin defects due to burns are a problem especially in emerging countries like India or Brazil. So our goal is clearly to be global. Perhaps our “Cutiss House” will become a “Cutiss Tower” in a few years. You have to think big to achieve big things.

8) How do you recharge your batteries?

With absolute peace and quiet. Of course, that’s not available in abundance in our networked world. That’s why I don’t impose clear offline times on myself. I don’t like strict rules, I prefer to find a healthy balance. It’s enough for me if I can take a relaxing bath for 20 minutes after work – no noise, no kids, no text messages. That’s where I can recharge.

9) Who do you call when you have a problem?

Before I call my husband or sister, I talk to myself – out loud and in English. This is not a joke. When I’m angry or have a problem, I talk to myself. I started doing that as a teenager and haven’t stopped until today. That’s why there are so many mirrors at home. (laughs)

10) What moment or person defined your career today?

It was in 2013, when I was invited to a business management course in the south of France as part of an EU funding program. I was able to take my husband and my then one-year-old daughter with me and thought to myself: great, we’ll take a week’s vacation on the beach and in between I’ll take some notes. But it turned out differently: we had a fantastic course instructor who was convinced that I was a natural. I will never forget that week. That was the moment I decided to become an entrepreneur.

11) When was the last time you doubted yourself?

Shortly after starting the company, I realized that I lacked the know-how to take the next step. I needed someone to add the necessary experience in business management to my drive and commitment. It was not easy to admit to myself that I was stuck. But today I’m glad I got the help I needed. It was the starting signal for our current team.

12) What are you most proud of?

Of what we are building as a company. But not in a business sense, but in a human sense. When I was able to hire my first employee, I cried with happiness. Our employees are becoming absolute experts in a field that is very trendy, modern and innovative. The future belongs to them – regardless of what happens to our company.

Even if she can now be found more often in boardrooms: In the lab, Daniela Marino feels completely in her element.

By Marlies Seifert on November 19, 2020

Article in SI Style: “You need to think big” Read More »

Fabienne Hartmann-Fritsch

Panel Discussion “Switzerland’s inventiveness makes the world a better place”

At the Credit Suisse REPLAY Panel three innovative Start-ups are presented. All of them are Spin-offs from the University of Zurich. Three female founders, together with
the Principal of the University of Zurich, Prof. Dr. Michael Schaepmann, talk about “Switzerland’s inventiveness”. Successful projects that could make the world a better place.

CUTISS’ Chief Clinical Officer Dr. Fabienne Hartmann-Fritsch talks about CUTISS’ bio-engineered skin which could become a hopeful treatment for burn victims. Further topics of the panel discussion are the financing, the hurdles and the role of women in leadership positions of young start-up companies.

> Introduction of Dr. Fabienne Hartmann-Fritsch starting at minute 07:22 – 13:35

> Panel discussion and Q&A as of minute 27:20

Panel Discussion “Switzerland’s inventiveness makes the world a better place” Read More »

CUTISS wins Top 100 Swiss Startup Award 2020

Zurich, Switzerland, September 10, 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has won the Top 100 Swiss Startup Award 2020, granted by a jury of 100 leading startup experts and investors within the framework of an award ceremony yesterday evening in Zurich. In 2019, CUTISS achieved rank six out of 100 and in 2018, the Company reached rank five out of 100. The win of this leading Swiss Startup award is reflecting the significant progress CUTISS achieved in the last twelve months: Despite the Covid-19 pandemic, the Company continued its activities, onboarded additional study centers and closed an oversubscribed Series B financing round, raising funds of more than CHF 20 Million. In addition, in August CUTISS received a positive opinion from the Paediatric Committee of the European Medicines Agency on the Company’s proposed Paediatric Investigation Plan for denovoSkin™ and significantly advanced its automation program. Most recently, staff members moved into a new office at the Biotechnopark in Schlieren (Zurich), next to the Company’s production and R&D facilities. CUTISS currently employs 28 employees, of which eight joined the Company since September 2019. About the Top 100 Swiss Startup Award The TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem: In the last 10 years, the event has featured 397 startups that have created more than 8’700 jobs and raised CHF 4.2 billion. Forty-two exits and two IPOs top off the achievements so far. Each year since 2011, the 100 most innovative and promising Swiss startups are picked by a jury of 100 leading investors and startup experts. www.top100startups.swiss/ About CUTISS AG CUTISS is a Swiss Life Science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich; denovoSkin™ was well tolerated by all patients with no safety issue reported. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ aims to improve life quality of elective (reconstructive treatments) patients as well and it can further be developed in terms of complexity by adding pigmentation. www.cutiss.swiss Contact CUTISS AG, CEO Dr. Daniela Marino, +41 44 244 36 60, info@cutiss.swiss Newsroom download press release as pdf

CUTISS wins Top 100 Swiss Startup Award 2020 Read More »

Logo CUTISS News final

CUTISS receives Positive Opinion from the Paediatric Committee of the EMA for denovoSkin™

Zurich, Switzerland, August 3, 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for its proposed Paediatric Investigation Plan (PIP) for denovoSkin™. The positive opinion is based on the non-clinical program, as well as data from the phase I safety clinical trial and the plans for the current phase IIb efficacy trials running in children and adults. The PDCO’s positive opinion on CUTISS’ PIP endorsed the Company’s program for denovoSkin™ as acceptable for assessment of safety and efficacy for the use in children from birth  to less than 18 years of age. The relevance of a Paediatric Investigation Plan (PIP) A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorisation holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorised and covered by intellectual property rights. About CUTISS AG CUTISS is a Swiss Life Science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich; denovoSkin™ was well tolerated by all patients with no safety issue reported. Phase II studies are currently ongoing in Switzerland and the European Union and are partially funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ aims to improve life quality of elective (reconstructive treatments) patients as well and it can further be developed in terms of complexity by adding pigmentation. Contact CUTISS AG, CEO Daniela Marino, +41 76 230 80 46, info@cutiss.swiss, www.cutiss.swiss Newsroom download press release as pdf

CUTISS receives Positive Opinion from the Paediatric Committee of the EMA for denovoSkin™ Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.